

15 April 2021

ZELIRA DELIVERS RECORD QUARTERLY REVENUE

- **Zelira achieved record sales revenue over the March 2021 quarter of A\$225,000, reflecting strong growth in SprinjeneCBD sales and licensing payments.**
- **Further growth expected from new products and new geographies.**
- **Management restructure underpins the Company's next growth phase.**

Zelira Therapeutics Ltd (ASX: ZLD, OTCQB: ZLDAF) is pleased to announce that it generated record quarterly product sales and licensing revenues of A\$225,000 for the March 2021 quarter (Q3 FY21), up 249% on the prior six months.

The Q3 FY21 performance is the strongest quarterly revenue reported for Zelira Therapeutics since its inception and clearly demonstrates the start of the Company's commercialisation ramp up. Revenue growth was driven largely by the successful December 2020 launch of the SprinjeneCBD oral care product in the USA.

With a suite of new products planned for launch over the next two quarters, Zelira Therapeutics is well placed to generate further growth in revenue via diversified income streams.

Zelira Therapeutics Managing Director, Dr Oludare Odumosu commented: "Our long-term focus to develop a portfolio of clinically validated and scientifically formulated cannabinoid medicine and consumer products is starting to bear fruit. The strong growth in March quarter revenue marks a key turning point for the Company. We are well placed to build on the March quarters' momentum and accelerate our progress in 2021 as we launch new products and expand into new geographies."

This announcement has been approved and authorised for release by the board of Zelira Therapeutics Limited.

- ENDS -

For further information please contact:

Company

Dr Oludare Odumosu
Managing Director & CEO
+1 909 855 0675
oodumosu@zeliratx.com

Investors

Market Eye Pty Ltd
ABN 54 137 305 527
Melbourne | Sydney
T: +61 3 9591 8900
F: +61 3 9591 8999
W: www.marketeye.com.au

About Zelira Therapeutics (www.zeliratx.com)

Australia

Level 26
140 St Georges Terrace
Perth WA 6000
AUSTRALIA
Tel: +61 8 6558 0886
Fax: +61 8 6316 3337
E: enquiries@zeliratx.com
W: www.zeliratx.com
ACN 103 782 378

USA

5110 Campus Drive
Suite 150
Plymouth Meeting, PA
19462
UNITED STATES OF AMERICA
Tel: +1 484-630-0650

Zelira Therapeutics Ltd is a leading global therapeutic medical cannabis company with access to the world's largest and fastest growing cannabis markets. Zelira owns a portfolio of proprietary revenue generating products and a pipeline of candidates undergoing clinical development that are positioned to enter global markets. The Company is focused on developing branded cannabinoid-based medicines for the treatment of a variety of medical conditions in its Rx business, including insomnia, autism and chronic non-cancer pain.

The Company has two proprietary formulations under the HOPE™ brand that are generating revenues in Australia, Pennsylvania and have been licensed in Louisiana and Washington D.C. with other states in the US expected to follow. Zelira is also generating revenue in Australia from its proprietary and patented Zenivol™ - a leading cannabinoid-based medicine for treatment of chronic insomnia. Zenivol™ has successfully completed the world's first Phase 1b clinical trial for chronic insomnia where it was found to be a safe and effective treatment. In 2020, Zelira partnered with SprinJene®Natural to develop and commercialise natural and organic oral care products under the SprinjeneCBD brand, as part of Zelira's OTC business. The SprinjeneCBD toothpaste product is the first of several scientifically formulated, hemp-derived, oral care products containing cannabinoids and based on the propriety and patented technology of Blackseed oil and Zinc.

The Company conducts its work in partnership with world-leading researchers and organizations including Curtin University in Perth, Western Australia; the Telethon Kids Institute in Perth; the University of Western Australia, in Perth; St. Vincent's Hospital in Melbourne, Australia; and the Children's Hospital of Philadelphia (CHOP) in the United States.